Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive F...
BUSINESS NEWS
May 05, 2026
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host...
3 views
0 likes
0 comments
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host...
Author: Cytokinetics
Read Original Article
